 Management Team Board of Directors Advisory Boards Community Involvement Strategic Alliances |
|
 |
Research and Development Expertise
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. The metabolic components
of diabetes and obesity are linked in many ways.
Amylin Pharmaceuticals’ Research
and Development team has significant experience in metabolic diseases and
is focused on investigating the biological actions and utilities of bioactive peptides and other compounds as potential drug candidates.
Collaborative Spirit
Amylin places a high value on teamwork and recognizes the enormous benefits
of collaborative arrangements. We actively investigate and pursue opportunities
that are a good fit with our therapeutic focus as well as our research, development
and commercial capabilities. We seek partners with the same values of integrity,
compassion and the commitment to develop novel treatments for the patients
we aim to serve. For more information about the compounds we are currently
developing, please click here to read about our product
pipeline.
Our Partnerships
Amylin has experience forming and operating strategic alliances,
ranging from enabling technologies and manufacturing, to full development
and commercialization agreements. Two of our major collaborations
include:
 |
Eli Lilly and Company
In September 2002 Amylin announced a global agreement with Eli Lilly and Company
to collaborate on the development and commercialization of exenatide (exendin-4).
Lilly and Amylin work together in a consensus fashion to co-develop and co-commercialize
exenatide.
view press release |
 |
Alkermes, Inc.
In May 2000, Amylin signed an agreement with Alkermes, Inc. for the development
and manufacturing of an injectable sustained release formulation of exenatide.
This development program utilizes Alkermes’ patented, FDA approved and
proprietary Medisorb® injectable sustained release drug delivery technology.
Based upon results obtained from initial feasibility studies, the goal of the
work under this agreement is to develop a sustained release formulation of exenatide
for the treatment of type 2 diabetes.
view press release |
Contact Us
Licensing inquiries may be sent via regular mail to the attention of Corporate
Development at the corporate headquarters address:
Amylin Pharmaceuticals, Inc.
9360 Towne Centre Drive
San Diego, California 92121
Please include non-confidential materials about your company, product
or technology along with a cover letter indicating your interest.
|
